CLINICAL ROLE -
Oncology Overview: Selpercatinib for RET-Positive Metastatic Non-Small Cell Lung Cancer
Selpercatinib is an oral selective RET kinase inhibitor approved for the treatment of metastatic RET fusion-positive non-small cell lung cancer and for metastatic thyroid cancer.
Clinical Overview: Lebrikizumab for Atopic Dermatitis
Lebrikizumab is a novel monoclonal antibody that binds with high affinity to the IL-13 protein to prevent the interaction between IL-13Rα1 and IL-4Rα, which blocks downstream signal activation along the IL-13 pathway.
Clinical Overview: Opzelura for Atopic Dermatitis
Ruxolitinib (Opzelura; Incyte) is a Janus kinase inhibitor indicated for patients 12 years of age or older whose atopic dermatitis is inadequately controlled with topical prescription therapies or when those therapies are inappropriate.
2 Clarke Drive Cranbury, NJ 08512